A score for decision making during percutaneous coronary intervention in acute myocardial infarction patients with multivessel disease
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The optimal percutaneous coronary intervention (PCI) strategy in patients with acute myocardial infarction (AMI) with multivessel disease (MVD) is uncertain. This study was designed to develop a novel and simple tool for assessing an individualized and optimized PCI strategy in AMI patients with MVD. Methods: In total, 5,025 patients with AMI from nine centers at two universities were enrolled in the prospective Convergent Registry of Catholic and Chonnam University for Acute Myocardial Infarction (COREA-AMI) registry from January 2004 through December 2009. From among them, we selected 2,630 patients with MVD who were treated by culprit-only or multivessel (MV) PCI. We investigated major adverse cardiac events (MACEs) during a 1-year clinical follow-up. Using a subgroup analysis, we extracted variables for use in the culprit only versus multivessel revascularization (CONVERSE) score, which showed a preference for MV PCI rather than culprit-only PCI for treating MVD. Results: The CONVERSE score was constructed using eight independent variables (1 point for each variable): age > 65 years, hypertension, diabetes mellitus, high Killip class (III or IV), low left ventricular ejection fraction (≤ 50%), low creatinine clearance (≤ 60 mL/min), high level of high-sensitivity C-reactive protein (≥ 2.0 mg/L), and left anterior descending artery or left main as the nonculprit vessel. The incidence of MACEs increased linearly with the CONVERSE score. The receiver operating characteristic curve showed that the cutoff value was 3 points. Conclusions: The results suggest that patients with a CONVERSE score of 3 or more should undergo MV PCI.
Abstract
Background/Aims: The optimal percutaneous coronary intervention (PCI) strategy in patients with acute myocardial infarction (AMI) with multivessel disease (MVD) is uncertain. This study was designed to develop a novel and simple tool for assessing an individualized and optimized PCI strategy in AMI patients with MVD. Methods: In total, 5,025 patients with AMI from nine centers at two universities were enrolled in the prospective Convergent Registry of Catholic and Chonnam University for Acute Myocardial Infarction (COREA-AMI) registry from January 2004 through December 2009. From among them, we selected 2,630 patients with MVD who were treated by culprit-only or multivessel (MV) PCI. We investigated major adverse cardiac events (MACEs) during a 1-year clinical follow-up. Using a subgroup analysis, we extracted variables for use in the culprit only versus multivessel revascularization (CONVERSE) score, which showed a preference for MV PCI rather than culprit-only PCI for treating MVD. Results: The CONVERSE score was constructed using eight independent variables (1 point for each variable): age > 65 years, hypertension, diabetes mellitus, high Killip class (III or IV), low left ventricular ejection fraction (≤ 50%), low creatinine clearance (≤ 60 mL/min), high level of high-sensitivity C-reactive protein (≥ 2.0 mg/L), and left anterior descending artery or left main as the nonculprit vessel. The incidence of MACEs increased linearly with the CONVERSE score. The receiver operating characteristic curve showed that the cutoff value was 3 points. Conclusions: The results suggest that patients with a CONVERSE score of 3 or more should undergo MV PCI.
참고문헌 (30)
- O'Gara PT, "2013 ACCF", AHA guideline for the management of ST-elevation myocardial infarction : executive summary : a report of the American College of Cardiology Foundation, Circulation, pp.2013, 127[DOI]
- Jneid H, "2012 ACCF", AHA focused update of the guideline for the management of patients with unstable angina, American Heart Association Task Force on Practice Guidelines, pp.J Am Coll Cardiol, 2012[DOI]
- Bainey KR, "Complete vs culprit-only revascularization for patients with multivessel disease undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction : a systematic review and meta-analysis", Am Heart J, 167, pp.1~14 (2014)
- Vlaar PJ, "Culprit vessel only versus multivessel and staged percutaneous coronary intervention for multivessel disease in patients presenting with ST-segment elevation myocardial infarction : a pairwise and network meta-analysis", J Am Coll Cardiol, 58, pp.692~703 (2011)
- Park HW, "Early-and late-term clinical outcome and their predictors in patients with ST-segment elevation myocardial infarction and non-STsegment elevation myocardial infarction", Int J Cardiol, 169, pp.254~261 (2013)
- Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology(ESC), "ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation", Eur Heart J, 33, pp.2569~2619 (2012)
- Wald DS, "Randomized trial of preventive angioplasty in myocardial infarction", N Engl J Med, 369, pp.1115~1123 (2013)
- Gershlick AH, "Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease : the CvLPRIT trial", J Am Coll Cardiol, 65, pp.963~972 (2015)
- Levine GN, "2015 ACC", AHA, AHA, pp.SCAI guideline for percutaneous coronary intervention and the 2013 ACCF, AHA guideline for the management of ST-elevation myocardial infarction[DOI]
- Roffi M, "2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation : task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology(ESC)", Eur Heart J, 37, pp.267~315 (2016)
- Shin DI, "Impact of occluded culprit arteries on long-term clinical outcome in patients with non-ST-elevation myocardial infarction : 48-month follow-up results in the COREA-AMI Registry", J Interv Cardiol, 27, pp.12~20 (2014)
- Levine GN, "2011 ACCF", AHA, American Heart Association Task Force on practice guidelines and the Society for Cardiovascular Angiography and Interventions, pp.Circulation, 2011[DOI]
- Kim MC, "What is optimal revascularization strategy in patients with multivessel coronary artery disease in non-ST-elevation myocardial infarction? Multivessel or culprit-only revascularization", Int J Cardiol, 153, pp.148~153 (2011)
- Binder RK, "Multi-vessel revascularization in ST-segment elevation myocardial infarction:where do we stand?", Eur Heart J, 37, pp.217~220 (2016)
- Zhang D, "Culprit vessel only versus multivessel percutaneous coronary intervention in patients presenting with ST-segment elevation myocardial infarction and multivessel disease", PLoS One, 9, pp.e92316~ (2014)
- Jensen LO, "Culprit only or multivessel percutaneous coronary interventions in patients with ST-segment elevation myocardial infarction and multivessel disease", EuroIntervention, 8, pp.456~464 (2012)
- Kornowski R, "Prognostic impact of staged versus"one-time"multivessel percutaneous intervention in acute myocardial infarction : analysis from the HORIZONS-AMI(harmonizing outcomes with revascularization and stents in acute myocardial infarction)trial", J Am Coll Cardiol, 58, pp.704~711 (2011)
- Bataille Y, "Interaction of chronic total occlusion and chronic kidney disease in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction", Am J Cardiol, 112, pp.194~199 (2013)
- Brener SJ, "Culprit-only or multivessel revascularization in patients with acute coronary syndromes : an American College of Cardiology National Cardiovascular Database Registry report", Am Heart J, 155, pp.140~146 (2008)
- Kelly DJ, "Complete Versus culprit-Lesion only PRimary PCI Trial(CVLPRIT) : a multicentre trial testing management strategies when multivessel disease is detected at the time of primary PCI : rationale and design", EuroIntervention, 8, pp.1190~1198 (2013)
- Marenzi G, "Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction", J Am Coll Cardiol, 44, pp.1780~1785 (2004)
- Schillinger M, "Statin therapy improves cardiovascular outcome of patients with peripheral artery disease", Eur Heart J, 25, pp.742~748 (2004)
- Huang HD, "Comparison of angiographic findings in patients with acute anteroseptal versus anterior wall ST-elevation myocardial infarction", Am J Cardiol, 107, pp.827~832 (2011)
- Cappelletti A, "Severity and prognostic localization of critical coronary artery stenoses : correlation with clinical control of major traditional risk factors", Coron Artery Dis, 23, pp.455~459 (2012)
- Marino M, "Comparison of outcomes of staged complete revascularization versus culprit lesion-only revascularization for ST-elevation myocardial infarction and multivessel coronary artery disease", Am J Cardiol, 119, pp.508~514 (2017)
- Sianos G, "The SYNTAX score : an angiographic tool grading the complexity of coronary artery disease", EuroIntervention, 1, pp.219~227 (2005)
- Serruys PW, "Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease", N Engl J Med, 360, pp.961~972 (2009)
- trial), "Am J Cardiol", 2014, 203~210
- Ntalianis A, "Fractional flow reserve for the assessment of nonculprit coronary artery stenoses in patients with acute myocardial infarction", JACC Cardiovasc Interv, 3, pp.1274~1281 (2010)
- Engstrom T, "Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease(DANAMI-3-PRIMULTI) : an open-label, randomized controlled trial", Lancet, 386, pp.665~671 (2015)